The WHO's upgrade of DRC Ebola risk to 'very high' reveals an outbreak that likely simmered undetected for weeks due to symptom overlap with malaria, a pattern seen in observational studies of prior Bundibugyo events (2007 Uganda n=116 cases; 2012 DRC n=77). This coverage underplays how Ituri province insecurity—marked by armed groups disrupting health access—has historically amplified transmission, as shown in non-RCT analyses of the 2018-2020 Ebola epidemic where conflict zones saw 2-3x higher secondary attack rates. No peer-reviewed RCTs exist for Bundibugyo-specific interventions, leaving reliance on repurposed monoclonal antibodies like REGN3479 and MBP134, prioritized by WHO based on limited Zaire-strain data from the PALM trial (RCT, n=681, no conflicts noted but industry-funded). Global spillover potential rises via porous Uganda borders and international workers, yet original reports overlook mutation risks in under-sequenced strains and the absence of approved vaccines. Contact tracing of 1,400+ individuals remains the sole evidence-based tool, per observational cohorts, but scaling it demands addressing root drivers like weak health infrastructure.